The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-I levels

Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor I (PAI-I) directly influence thrombus formation and degradation and thus risk for arterial thrombosis. We report here results from a genetic analysis of plasma t-PA and PAI-I levels in a large population-based sample from the PREVEND study in Groningen, the Netherlands (n = 2,527). We measured polymorphisms from genes of the fibrinolytic system, the renin-angiotensin system (RAS), and the bradykinin system. We found that males had higher levels of natural-log transformed t-PA, and PAI-I (P < 0.01) compared to females. When stratifying females by menopausal status, PAI-I levels were only significantly different between pre-menopausal females and males (p < 0.001). Furthermore, we found that age, body mass index, and waist-to-hip ratio were significant predictors of t-PA and PAI-I in both females and males, and that the regression relationships between these factors and plasma t-PA and PAI-I were dependent on gender. In addition,we found that the PAI-I 4GI5G polymorphism was a significant predictor of PAI-I levels in both females and males, that the angiotensin II type I receptor A1166C was a significant predictor of t-PA and PAI-I levels in females, and that the bradykinin receptor B2 58CT polymorphism was a significant predictor of t-PA levels in females. In conclusion, this large population-based study showed that t-PA and PAI-I levels are determined by several demographic and genetic factors involved in the fibrinolytic, PAS and bradykinin system. In addition, the results support the idea that the biology of t-PA and PAI-I is different between females and males.